<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573751</url>
  </required_header>
  <id_info>
    <org_study_id>EPIVER</org_study_id>
    <nct_id>NCT04573751</nct_id>
  </id_info>
  <brief_title>The EPIVER Randomized Controlled Trial</brief_title>
  <acronym>EPIVER</acronym>
  <official_title>Intracoronary Administration of Epinephrine and Verapamil in the Refractory No-reflow Phenomenon in Patients With Acute Myocardial Infarction: The EPIVER Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial aims to estimate the efficacy and safety of the intracoronary administration of&#xD;
      adrenalin, verapamil, as well as their combination compared to standard treatment in patients&#xD;
      with STEMI and refractory coronary no-reflow despite conventional treatment during&#xD;
      percutaneous coronary intervention (PPCI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for&#xD;
      treating acute ST-segment elevation myocardial infarction (STEMI). The main goals are to&#xD;
      restore epicardial infarct-related artery patency and to achieve microvascular reperfusion as&#xD;
      early as possible. No-reflow is the term used to describe inadequate myocardial perfusion of&#xD;
      a given coronary segment without angiographic evidence of persistent mechanical obstruction&#xD;
      of epicardial vessels and it refers to the high resistance of microvascular blood flow&#xD;
      encountered during opening of the infarct-related coronary artery. Despite optimal&#xD;
      evidence-based PPCI, myocardial no-reflow can still occur, negating many of the benefits of&#xD;
      restoring culprit vessel patency, and is associated with a worse in-hospital and long-term&#xD;
      prognosis.&#xD;
&#xD;
      According to clinical guidelines, nitrates, adenosine, platelet IIb / IIIa receptor&#xD;
      inhibitors and thrombus extraction can be used to prevent and treat this complication.These&#xD;
      methods have demonstrated the ability to improve coronary blood flow in experiment and small&#xD;
      clinical trials, however, limiting the zone of myocardial necrosis and improving disease&#xD;
      outcomes have not been achieved.&#xD;
&#xD;
      The search for new methods of influencing the pathogenetic links of this complication is&#xD;
      urgent. One of the main potentially reversible factors in the pathogenesis of the no-reflow&#xD;
      phenomenon, along with microvascular obstruction, is microvascular arteriolar spasm. Thus,&#xD;
      this problem of emergency cardiology remains relevant and requires further research, new&#xD;
      methods of prevention and treatment.&#xD;
&#xD;
      Aside from exerting beta-1 agonist properties at higher doses and increasing the inotropic&#xD;
      and chronotropic stimulation of the myocardium, epinephrine may, at lower doses, exert potent&#xD;
      beta receptor agonist properties that mediate coronary vasodilatation. Another drug with a&#xD;
      pronounced coronary vasodilation effect is verapamil.&#xD;
&#xD;
      Based on the pharmacodynamic effects of epinephrine and verapamil, it is expected to increase&#xD;
      the vasodilating effect when they are used together, due to the additive type of synergistic&#xD;
      interaction, which will improve coronary microcirculation after PCI in patients with acute&#xD;
      myocardial infarction and refractory no-reflow phenomenon.&#xD;
&#xD;
      Currently, in clinical practice, there is a possibility of very sensitive diagnosis of&#xD;
      microvascular obstruction (MVO) using magnetic resonance imaging (MRI), as well as the area&#xD;
      of the coronary reserve according to dynamic perfusion scintigraphy of the myocardium. It is&#xD;
      advisable to evaluate the effectiveness of treatment of the no-reflow phenomenon using these&#xD;
      methods.&#xD;
&#xD;
      The trial aims to estimate the efficacy and safety of the administration of intracoronary&#xD;
      epinephrine, verapamil, as well as their combination versus to standard treatment in patients&#xD;
      with STEMI and refractory coronary no-reflow despite conventional treatments during PPCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>month 1</time_frame>
    <description>Mortality rate (percent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New onset or worsening acute heart failure</measure>
    <time_frame>month 1</time_frame>
    <description>The rate (percent) of patients experiencing new onset or worsening acute heart failure. Congestion characterized by dyspnea, edema, rales, jugular venous distention and need to increase diuretic doses is a hallmark of acute heart failure prompting hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in myocardial infarction (TIMI) 3</measure>
    <time_frame>hour 1</time_frame>
    <description>The rate of patients (percent) who achieved TIMI 3 coronary blood flow after percutaneous coronary intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic/diastolic blood pressure</measure>
    <time_frame>minute 3</time_frame>
    <description>Change in systolic/diastolic blood pressure values (mmHg) before and after intracoronary verapamil/epinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment resolution</measure>
    <time_frame>hour 72</time_frame>
    <description>Degree of ST segment resolution on ECG (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin I release</measure>
    <time_frame>hour 72</time_frame>
    <description>Concentration of troponin I (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV EF</measure>
    <time_frame>day 10</time_frame>
    <description>Left ventricular ejection fraction (LV EF) (percent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury</measure>
    <time_frame>day 2</time_frame>
    <description>Total volume (mL) of microvascular obstruction, myocardial necrosis, edema, and hemorrhagic impregnation according to MRI data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPECT-based coronary reserve</measure>
    <time_frame>day 7</time_frame>
    <description>Coronary reserve will be measured by cardiac single photon emission computed tomography (SPECT) with technetium-99m-labeled methoxy-isobutyl isonitrile (99mТсMIBI) at rest and during pharmacological stress-test (counts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate values</measure>
    <time_frame>minute 3</time_frame>
    <description>Change in heart rate values (beat per minute) before and after intracoronary verapamil/epinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV EDV</measure>
    <time_frame>10 days</time_frame>
    <description>Left ventricular end-diastolic volume (LV EDV) (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV ESV</measure>
    <time_frame>day 10</time_frame>
    <description>Left ventricular end-systolic volume (LV ESV) (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV WMSI</measure>
    <time_frame>day 10</time_frame>
    <description>Left ventricular wall motion score index (LV WMSI) (conventional units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmias</measure>
    <time_frame>minute 5</time_frame>
    <description>Frequency of arrhythmias (atrial fibrillation, atrial flutterу, supraventricular tachycardia, premature ventricular contractions, ventricular tachycardia, conduction disorders and other heart rhythm disorders) after intracoronary administration verapamil and/or epinephrine</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>No-Reflow Phenomenon</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No intracoronary epinephrine and verapamil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracoronary bolus epinephrine injection requires two ampoules each of 1:1,000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline solution (to 20 μg/mL epinephrine solution); therefore, a 5-mL syringe contains 100 μg of epinephrine. Intracoronary epinephrine will be administered at a dose of 100 μg and at a lower dose of 80 μg in patients with blood pressure &gt;160 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracoronary verapamil is administered at a dose of 0.5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine + verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracoronary administration of epinephrine at a dose of 80-100 μg and verapamil at a dose of 0.5 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.</description>
    <arm_group_label>Standard therapy</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.</description>
    <arm_group_label>Epinephrine</arm_group_label>
    <other_name>Epi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.</description>
    <arm_group_label>Verapamil</arm_group_label>
    <other_name>Ver</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine + verapamil</intervention_name>
    <description>Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.</description>
    <arm_group_label>Epinephrine + verapamil</arm_group_label>
    <other_name>Epi+Ver</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with ST-elevation myocardial infarction&#xD;
&#xD;
          -  Infarct-related artery TIMI flow grade 0-2 during the interventional procedure after&#xD;
             the initial opening of the vessel.&#xD;
&#xD;
          -  Written the informed consent to participate in research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to undergo or contra-indications for MRI or SPECT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vyacheslav V Ryabov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Research Institute, Tomsk NRMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vyacheslav V. Ryabov, MD, Phd</last_name>
    <phone>+73822553689</phone>
    <email>rvvt@cardio-tomsk.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanislav V. Dil</last_name>
    <phone>+79131006366</phone>
    <email>dil.stanislav@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Research Institute, Tomsk NRMC</name>
      <address>
        <city>Tomsk</city>
        <state>Tomsk Region</state>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislav V Dil</last_name>
      <phone>+79131006366</phone>
      <email>dil.stanislav@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary PCI</keyword>
  <keyword>No-reflow</keyword>
  <keyword>Intracoronary epinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>No-Reflow Phenomenon</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

